ClinicalTrials.gg
RecruitingNCT07421713Updated Oct 23, 2026

A Study Evaluating the Performance of Using AI Software and Chest X-rays to Screen for Osteoporosis as Compared to Standard DXA Scans in Patients 50 Years and Older

An observational study in Osteoporosis, Osteopenia, sponsored by Promedius Inc. Recruiting at 3 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Promedius Inc · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 23, 2026Site recruiting status changedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
595
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Osteoporosis with a site in United Kingdom — 8 open to participants now, 9 under way, none of them phase 3. Osteoporosis · United Kingdom.

Planned enrollment
9th of 21
595 · median 440
Started
2026
with 1 other
Observational
21 of 57
7 open now
Registered
57th of 57
by date

Among the 57 studies in Osteoporosis with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2026, is one of 21 observational ones, and was the 57th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 57 studies in Osteoporosis with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Osteoporosis with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this study is to assess the performance of an artificial intelligence software (Osteo Signal) in detecting osteoporosis risk in adults 50 years and older. The main question it aims to answer is: What is the accuracy of the software in detecting osteoporosis risk on chest x-ray images as compared to the standard technique of dual-energy x-ray absorptiometry (DXA)? There is no direct involvement of participants in this study as it will use data from individuals who have already had a chest x-ray and a DXA scan taken in the past.

03

Conditions studied

  • Osteoporosis, Osteopenia

Keywords

  • Osteoporosis
  • Bone Diseases, Metabolic
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients selected hospitals in the Netherlands and UK that have previously had chest x-rays and DXA scans

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥50 years at the time of chest X-ray
  2. Availability of

    1. Posteroanterior (PA) Chest X-ray and
    2. DXA scan with a valid T-score measurement where both the DXA scan and Chest x-ray examinations were performed within 6 months (182 days) of each other and
    3. Available X-ray and DXA scans performed on or after 01-Jan-2010.
  3. Complete metadata (sex and age) available on PACS or hospital records.

Exclusion criteria

Exclusion Criteria:

  1. Non-diagnostic Quality or Incomplete Imaging of:

    1. DXA scan inadequacy: Missing T-score from a technically inadequate scan.
    2. PA Chest X-ray technical inadequacy: Non-PA projection, significant motion artefacts, inadequate visualisation of thoracic structures, or missing DICOM metadata.
    3. Image format incompatibility: Non-DICOM format or corrupted image files that would prevent AI analysis
    4. PA Chest X-ray > ±6 months from the date of the DXA scan.
  2. Previous diagnosis or treatment of Osteoporosis prior to the DXA scan used in the Study.

    1. diagnosis of osteoporosis (T-score ≤-2.5), or current/recent anti- osteoporotic medications, within 12 months prior to the DXA scan used in the study.
    2. Current or recent anti-osteoporotic medications for 3 months (91 days) continuously prior to the Chest x-ray used in the Study.
  3. Diagnosis of any metabolic bone disease prior to the DXA scan used in the study.
  4. Diagnosis of metabolic bone disease other than Osteoporosis or Osteopenia, up to a maximum of 3 months (91 days) after the DXA scan.
  5. Major Chest Wall or Spinal Deformities, including but not limited to:

    1. Severe structural deformities: Thoracic scoliosis with Cobb angle >40°, severe kyphosis, or chest wall deformities (pectus excavatum/carinatum) affecting >30% of the thoracic cage.
    2. Surgical hardware: Previous thoracic/spinal surgery with metallic implants obscuring anatomical landmarks required for AI analysis.
    3. Pathological conditions: Extensive pulmonary consolidation, pleural effusion, lesions or masses obscuring >30% of thoracic skeletal structures
  6. Subject has opted out of confidential data being used for research purposes
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
595 participants (estimated)
Patient registry
No

Interventions

  • DeviceOsteo Signal

    Artificial Intelligence (AI) software

06

What researchers measure

Primary outcomes

  1. Two class bone status classification (osteoporosis/non osteoporosis)

    Device output against the lowest DXA as measured by sensitivity, specificity, and area under the ROC curve (AUC)

    Time frame: At a time following the participant having had a chest x-ray and DXA scan within 6 months of each other

Secondary outcomes

  1. Three class bone status classification (osteoporosis/osteopenia/normal)

    Device output against the lowest DXA as measured by area under the ROC curve (AUC), overall per cent agreement, and weighted Cohen's kappa

    Time frame: At a time following the participant having had a chest x-ray and DXA scan within 6 months of each other

  2. Classification for osteoporosis and osteopenia

    Positive predictive value (PPV) and negative predictive value (NPV) for osteoporosis and osteopenia classifications

    Time frame: At a time following the participant having had a chest x-ray and DXA scan within 6 months of each other

07

Study locations

2 of 3 sites recruiting
  • Erasmus University Medical Center Rotterdam
    Rotterdam, Netherlands 3015 GD, Netherlands
    Not yet recruiting
    • Jacob J Visser, Musculoskeletal Radiologist · Principal investigator
  • Mid and South Essex NHS Foundation Trust
    Westcliff-on-Sea, Essex SS0 0RY, United Kingdom
    Recruiting
    • Anupama C Nandagudi, Consultant Rheumatologist · Principal investigator
  • Barts Health NHS Trust
    London, E1 4DG, United Kingdom
    Recruiting
    • Giuseppe Ruocco · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — No IPD will be shared. The trial data is proprietary and part of a product development program.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Mar 2026 → Nov 2026 and completion Mar 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Feb 10, 2026
Primary completionEst.
Nov 30, 2026was Mar 2026
CompletionEst.
Dec 31, 2026was Mar 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. Mid and South Essex NHS Foundation Trust is now Recruiting
Show site
  • Erasmus University Medical Center Rotterdam · Rotterdam, Netherlands
Show 1 removed
  • Erasmus University Medical Center Rotterdam, · Rotterdam, Netherlands
Oct 23, 2026
Primary completion
Mar 2026→Nov 30, 2026
Oct 23, 2026
Study completion
Mar 2026→Dec 31, 2026
Oct 23, 2026
Contact
Study contact changed: k•••@medilife.net · •••9062→j•••@promedius.ai · •••3509; j•••@promedius.ai · •••3509→d•••@promedius.ai · •••1125. See the current contact
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added, 1 site removed. Mid and South Essex NHS Foundation Trust is now Recruiting
    Show site
    • Erasmus University Medical Center Rotterdam · Rotterdam, Netherlands
    Show 1 removed
    • Erasmus University Medical Center Rotterdam, · Rotterdam, Netherlands
    Primary completion Mar 2026→Nov 30, 2026
    Study completion Mar 2026→Dec 31, 2026
    Contact Study contact changed: k•••@medilife.net · •••9062→j•••@promedius.ai · •••3509; j•••@promedius.ai · •••3509→d•••@promedius.ai · •••1125. See the current contact
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07421713
Lead sponsor
Promedius Inc
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Feb 10, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 23, 2026

Study contacts

Jung Jinho, Ph.D. Candidate in Pharmacy
Contact
jhjung@promedius.ai
+821083113509
DongKeun Lee, B.S.
Contact
dklee@promedius.ai
+82 1062631125
Jacob J Visser, Musculoskeletal Radiologist
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion